Antifibrotic agent

This page covers all Antifibrotic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases, TGF-β pathway; multiple pro-fibrotic cytokines, TGF-β signaling pathway; fibroblast proliferation.

Targets

Pirfenidone: TGF-β pathway; Nintedanib: FGFR, VEGFR, PDGFR tyrosine kinases · TGF-β pathway; multiple pro-fibrotic cytokines · TGF-β signaling pathway; fibroblast proliferation

Marketed (2)

• pirfenidone or nintedanib · Hospices Civils de Lyon · Pulmonary/Respiratory
  Pirfenidone and nintedanib are antifibrotic agents that reduce fibroblast proliferation and collagen deposition to slow lung fibrosis progression.
• Pirfenidone Capsules · Shanghai Zhongshan Hospital · Pulmonology / Respiratory
  Pirfenidone reduces fibroblast proliferation and collagen production by inhibiting multiple pro-fibrotic cytokines and growth factors.

Phase 3 pipeline (2)

• pirfenidone 8% gel · Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. · Dermatology
  Pirfenidone reduces skin fibrosis and inflammation by inhibiting fibroblast proliferation and transforming growth factor-beta (TGF-β) signaling.
• COL-1620 · Merck KGaA, Darmstadt, Germany · Fibrosis / Respiratory
  COL-1620 is a selective inhibitor of collagen-producing fibroblasts that reduces excessive collagen deposition in fibrotic tissues.